Healix

Real World Experience of Bezlotoxumab for Prevention of Recurrent C. Difficile Infection: A Single-Arm Multicenter Pilot Study in Office Infusion Centers

Timothy E. Ritter – Texas Digestive Disease Consultants, Southlake, TX
Richard L. Hengel – Atlanta ID Group, Atlanta, GA; Piedmont Healthcare, Atlanta, GA
Curtis J. Fitzsimmons – Plaza Infectious Disease, Kansas City, MO; University of Missouri-Kansas City, MO
Kevin Garey – University of Houston College of Pharmacy, Houston, TX
Lucinda J. Van Anglen – Healix Infusion Therapy, Sugar Land, TX
Claudia P. Schroeder – Healix Infusion Therapy, Sugar Land, TX
Stephen W. Marcella – Center for Observational and Real World Evidence, Merck & Co., Inc., Rahway, NJ, USA
John J. Hawkshead – Center for Observational and Real World Evidence, Merck & Co., Inc., Rahway, NJ, USA

View Poster

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound